InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Last trade$1.15
Day change-$0.03 (-2.54%)
Day range$1.09 – $1.23
Volume569,270
Market cap$174M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for IFRX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for IFRX.
Recent news
Company coverage with links to the original publishers.
InflaRx N.V. (IFRX) has formed a hammer chart pattern after an 8.5% weekly decline, suggesting potential trend reversal. The stock is supported by rising analyst optimism, with consensus EPS estimates increasing 29.5% over the last 30 days. IFRX holds a Zacks Rank #2 (Buy) rating, placing it in the top 20% of rated stocks.
InflaRx announced pre-clinical data demonstrating that izicopan, an oral C5a receptor inhibitor, robustly inhibited inflammatory responses and provided renal protection in kidney disease models. The data showed significant improvements in renal function markers and histopathological scores in both acute kidney injury and progressive renal injury models. Structural modeling revealed izicopan's differentiated molecular profile with reduced drug-drug interaction potential compared to competitors.
InflaRx N.V. (Nasdaq: IFRX) announced it received a notice from Nasdaq on March 11, 2026, indicating that its ordinary shares have closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until September 7, 2026, to regain compliance, with a potential additional 180-day grace period if it transfers to the Nasdaq Capital Market. The notice has no immediate effect on trading.
InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.
InflaRx N.V. announced the pricing of its public offering of 8,250,000 ordinary shares and 6,750,000 pre-funded warrants at $2.00 per share. The company intends to use the net proceeds to fund the clinical development of its pipeline candidates and for general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.